<DOC>
	<DOCNO>NCT02227017</DOCNO>
	<brief_summary>Study establish relative bioavailability TPV oral solution formulation ( 500 mg coadministered RTV oral solution 200 mg ) TPV capsule formulation ( 500 mg coadministered RTV capsule 200 mg ) , treatments steady-state fasted fed condition healthy male female volunteer .</brief_summary>
	<brief_title>Relative Bioavailability Tipranavir ( TPV ) /Ritonavir ( RTV ) Steady State Administered Oral Solutions v . Capsules Fed Fasted State Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Male female subject 18 65 year age inclusive 2 . A Body Mass Index ( BMI ) : ≥18.5 ≤35 kg/m2 3 . Signed informed consent prior performance study procedures 4 . Ability swallow multiple large capsule without difficulty 5 . Screening laboratory value within normal range . Inclusion subject abnormal laboratory value subject approval BI trial clinical monitor 6 . Acceptable medical history , physical examination , 12lead ECG screen 7 . Willingness abstain follow start 5 day prior administration study medication end study : Grapefruit grapefruit juice , red wine , Seville oranges , St. John 's Wort Milk Thistle 8 . Willingness abstain follow start 3 day prior administration study medication end study : Garlic supplement methylxanthine contain food drink ( include coffee , tea , cola , energy drink , chocolate , etc . ) , apples apple juice 9 . Willingness abstain overthecounter herbal medication duration study 10 . Are nonsmoker 11 . Willingness abstain vigorous physical exercise intensive pharmacokinetic day 10 , 11 , 14 , 15 12 . Reasonable probability completion study 1 . Participation another trial investigational medicine within 2 month prior Day 0 study 2 . Female subject reproductive potential : Have positive pregnancy test Have use barrier method contraception least 3 month prior participation study Are willing use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 60 day completion/termination trial Are breastfeed Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior Day 0 duration study . Due long halflife , subject use DepoProvera® within 6 month prior Day 1 exclude participation study Use hormone replacement therapy within 1 month prior Day 0 anytime study 3 . Use medication list Protocol within 30 day prior Day 0 study 4 . Administration antibiotic within 15 day prior Day 0 anytime study 5 . History acute illness within 60 day prior Day 0 Subjects exclude acute illness occur 60 day prior Day 0 , opinion investigator , subject qualify healthy volunteer 6 . Serological evidence hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) 7 . Serological evidence exposure HIV 8 . Alcohol substance abuse within 1 year prior screen study 9 . Blood plasma donation within 30 day prior Day 0 study 10 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer TPV , RTV subject 11 . Subjects take ( within 7 day prior Day 0 ) overthecounter prescription medication , opinion investigator consultation sponsor 's clinical monitor , might interfere absorption , distribution , metabolism study medication 12 . Known hypersensitivity sulphonamide class drug 13 . Known hypersensitivity TPV , RTV , antiretroviral drug ( market experimental use part clinical research study ) 14 . Known elevate liver enzyme past trial compound 15 . Known allergy nut nut product ( A spoonful peanut hazelnut butter take immediately administration TPV RTV oral solution , help mask taste solution ) 16 . Inability adhere protocol 17 . Inability consume standard highfat meal 18 . Cautions warning package insert , opinion investigator , constitute ground subject exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>